Axa S.A. acquires 1,508 shares of Bio-Techne Co.

According to the company's most recent filing with the Securities and Exchange Commission, Axa S.A. acquired more shares in Bio-Techne Corporation during the third quarter. The submission was filed on the company's behalf.

‍

The fund spent over $428,000 to buy 1,508 shares of stock in the biotechnology business, increasing its total investment to roughly $428,000.

‍

Numerous institutional investors have increased their holdings in the company's shares.

These modifications were made by these investors in reaction to recent market occurrences.

‍

Cullen Frost Bankers, INC raised the percentage of its capital invested in Bio-Techne by 488.2% during the third quarter. Cullen Frost Bankers INC currently owns 100 shares in the biotechnology industry, having added 83 shares during the most recent fiscal quarter to bring their total number of shares to 100.

‍

These shares are presently worth $28,000 on the market.

‍

During the third quarter, BerganKDV Wealth Management LLC made a new investment in Bio-Techne for about $38,000.

‍

Ellevest INC boosted its Bio-Tech investment by 119.0% during the third quarter of the fiscal year.

‍

Ellevest INC now owns 173 shares of the biotechnology company's stock, worth $49,000, after acquiring an additional 94 shares during the most recent fiscal quarter.

‍

Quantbot Technologies L.P. invested money and created a new investment in Bio-Tech throughout the first three months of the year. The cost of filling the post was around $56,000.

‍

Finally, the value of Global Retirement Partners LLC's stake in Bio-Techne climbed by 34.8% during the fiscal third quarter. Global Retirement Partners LLC now owns 209 shares of the biotechnology company's stock, which is worth $62,000, after acquiring an additional 54 shares in the last quarter.

‍

Institutional investors and hedge funds hold 23.92% of the company's stock.

‍

Brenda S. Furlow, Senior Vice President and General Counsel of the company, sold 800 shares of stock on December 7th, bringing us to another recent business development.

‍

A total of $65,608.00 of stock was exchanged at an average price of $82.01, resulting in a revenue total of $65,608.00.

‍

The senior vice president has 26,092 shares with a market value of about $2,139,804.92. Employee ownership of the corporation controls a total of 4.45% of its equity.

‍

The price of a share of tech stock at the start of trade on Thursday was $74.91.

The stock's moving average over the previous 50 days was $79.56, while the moving average over the previous 200 days was $81.61.

‍

In the previous 52 weeks, Bio-Techne Co. saw a low point of $68 and a high point of $113.81.

‍

With a market value of $11.78 billion, a price-to-earnings ratio of 46.53, a price-to-earnings-growth ratio of 2.38, and a beta value of 1.24, the firm is a profitable investment.

‍

These measurements show the company has enough financial resources.

The quick ratio to the current ratio is 4.40, whereas the quick ratio to the current ratio is 3.15.

‍

Equity debt is a 0.11 ratio. Also, the company recently declared a quarterly dividend, which was issued the next day after being paid out on February 27th.

‍

A $0.08 dividend payment was sent on February 13th as a dividend to investors whose information was already on file.

‍

This results in a $0.32 yearly dividend payout and a 0.43% dividend yield. This indicates an increase over Bio-last Techne's quarterly dividend distribution of $0.02, which represented a dividend payment. The last day for owners to collect a dividend for this investment is February 10th, a Friday. Over 19.88% of the total may be attributable to payment technologies.

‍

Several research firms have recently shown interest in information technology (I.T.). In a report published on Monday, December 12th, Citigroup raised Bio-rating Techne's from "neutral" to "buy" and raised their price target for the stock from $81.25 to $100.00. In a research note released on Monday, February 6th, the Royal Bank of Canada lowered their price objective for Bio-Techne from $89.00 to $80.00 and rated the stock as "sector perform." On Tuesday, January 10th, Wells Fargo & Company upgraded Bio-Techne from an "underweight" rating to an "equal weight" rating.

‍

The company's price goal was set at $90.00, while the stock's price objective was upgraded from $81.25 to $100.00. The Royal Bank of Canada published a research note on Monday, February 6th, lowering their price objective for Bio-Techne from $89.00 to $80.00 and rating the stock as "sector perform." Wells Fargo & Company upgraded Bio-Techne from an "underweight" rating to an "equal weight" rating and set a price objective of $90.00 on the company in a report released Tuesday, January 10th.

‍

According to the analysis, the share price is expected to reach $90.00 during the next twelve months. In a research report made public on Monday, December 5th, Stephens reduced their price objective on Bio-Techne to $105.00. Notwithstanding this adjustment, they maintained their "overweight" rating on the stock.

‍

Bio-shares Techne's reduce from a "buy" rating to a "hold" rating in a research piece released on Thursday, January 26th.

‍

This was the rating's final and most important adjustment. Seven experts have suggested that investors purchase the stock, while only three have advised them to keep their shares.

‍

According to Trade Algo, the company is presently rated as having a consensus "Moderate Buy" rating, and its target price is currently assessed as having a consensus value of $104.36.

‍